HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetic Manufacturers Preparing For MoCRA Safety Substantiation Should Look To EU – Attorneys

Executive Summary

Manufacturers looking for a model of safety substantiation in order to comply with the US Modernization of Cosmetics Regulation Act of 2022 should consider the framework required by the EU’s Cosmetic Products Regulation, says Steptoe & Johnson associate Surya Kundu. Attorneys also discussed new requirements for adverse event reporting during a FDLI webinar on MoCRA.

You may also be interested in...



Canada’s Cosmetic Animal-Testing Ban: What It Means For China Testing, New Ingredients, USA

Canada’s prohibitions on cosmetic animal testing enter into force in December, largely in line with EU, California and other bans around the globe, but with some notable distinctions. “Now it's really time to increase the pressure in the US – action can't be far behind,” says Brandi Halls, chief ethics officer at Lush Cosmetics, North America.

FDA Will Be Motivated To Bring Enforcement Action Under MoCRA; ‘Get Your Ducks In a Row’

The US Food and Drug Administration will have new cosmetics requirements to enforce under the Modernization of Cosmetic Regulations Act, as well as new funds and pressure “to make a show of this,” Locke Lord attorneys said in the law firm’s 31 May “MoCRA and You” webinar.

US Cosmetics Companies Doing Gap Analysis, Awaiting FDA Instruction In MoCRA’s First Year

Amin Talati Wasserman attorney Angela Diesch discusses the priorities, questions and concerns among companies facing end-of-year deadlines under the Modernization of Cosmetic Regulations Act enacted in the final days of 2022.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel